{
      "ptx_code": "PTX146",
      "chem_name": "Lenvatinib",
      "casrn": "417716-92-8",
      "dtxsid": "DTXSID50194605",
      "smiles": "COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4CC4)C=C3)=C2C=C1C(N)=O",
      "inchikey": "WOSKHXYHFSIKNG-UHFFFAOYSA-N",
      "label": "PTX146 | Lenvatinib",
      "pubchem_cid": "9823820",
      "drugbank_id": "DB09078",
      "use_class": "Pharmaceutical",
      "tox_class": "Hepatotoxicity; Nephrotoxicity; Cardiotoxicity",
      "formula": "C21H19ClN4O4",
      "chem_name_user": "Lenvatinib",
      "mw_g_mol": "426.86",
      "solubility_h2o_mol_liter": "1.09e-06",
      "source_solubility_h2o": "COMPTOX (OPERA)",
      "henry_coefficient_atm_m3_mol": "1.68e-11",
      "source_henry": "COMPTOX",
      "log_kaw_kh_rt": "9.16",
      "source_kaw": "LSER",
      "pka_acid": "",
      "pka_base": "",
      "source_pka": "ACD/GALAS",
      "log_kow_liter_liter": "3.01",
      "source_kow": "mean of ACD consensus and KOWWIN",
      "log_dlipw_ph74_liter_liter": "3.16",
      "source_dlipw": "klipW (?mw = 1)",
      "freely_dissolved_fraction": "0.46",
      "density_kg_liter": "1.46",
      "source_density": "COMPTOX",
      "boiling_point": "560.745; 627.242; 657.46",
      "source_boiling_point": "CompTox, predicted (TEST; ACD/Labs; EPISUITE)",
      "melting_point": "195.0; 250.178; 286.15",
      "source_melting_point": "CompTox, predicted (OPERA 2.6; TEST; EPISUITE)",
      "vapor_pressure": "1.2e-15; 6.98232e-13; 1.2589254117941663e-09",
      "source_vapor_pressure": "CompTox, predicted (ACD/Labs; TEST; OPERA 2.6)",
      "baseline_drerio": "124.00",
      "baseline_dmagna": "87.40",
      "baseline_celegans": "192.06",
      "baseline_xlaevis": "90.95",
      "baseline_dmelanogaster": "754.16",
      "baseline_cells": "3.96e-05",
      "baseline_cells_generic_micromole_liter_free_ec10": "1.82e-05",
      "moa_drugbank": "Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFR\u00ce\u00b1), KIT, and RET.",
      "protein_binding": "In vitro binding of lenvatinib to human plasma proteins ranged from 98% to 99%.",
      "moa_t3db": "",
      "aop": [],
      "targets": []
}